The Company

Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance including immuno-suppression, exhausted T cells, and poor tumor immunogenicity.

Kineta is a leader in developing fully human antibody drugs directed against novel innate immune targets. Kineta’s focus on innate immunity differentiates it from other immuno-oncology companies that are primarily focused on adaptive immunity and T cell focused therapies. With KVA12123 in an ongoing Phase 1/2 clinical studying and the lead anti-CD27 agonist mAb in preclinical development, Kineta believes it is positioned to achieve multiple value-driving catalysts.

Kineta has assembled an experienced management team, a seasoned research and clinical team, an immuno-oncology focused scientific advisory board, and a leading intellectual property position to advance its pipeline of potential novel immunotherapies for cancer patients.


Leadership Team

Kineta is led by a team with diverse talents who are recognized for their expertise in drug development, corporate finance and success in bringing new pharmaceutical therapies to market.

Chief Executive Officer


Chief Financial Officer

General Counsel

Chief Scientific Officer

EVP Investor Relations & Business Development


Board of Directors




Chief Executive Officer & Director

Scientific Advisory Board

Netherlands Cancer Institute

Oregon Health & Science University

MD Anderson Cancer Center

Yale School of Medicine

Fred Hutchinson Cancer Center